• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates
Home » Abbott wins European approval for bioresorbable stent

Abbott wins European approval for bioresorbable stent

January 10, 2011 By MassDevice staff

ABT logo

Abbott Laboratories (NYSE:ABT) landed approval from European regulators for its drug-eluting bio-resorbable Absorb stent.

The Abbott Park, Ill.-based healthcare products conglomerate said the device, like other stents, works by opening up and providing support to clogged arteries. Unlike its metal counterparts, however, the device is designed to dissolve within approximately two years after implantation, according to Abbott. The device is comprised of polylactide, a bio-compatible substance used in medical implants such as resorbable sutures. Because it eventually disappears, the necessity to treat stent recipients with long-term dual anti-platelet therapy "may be reduced," the company said.

Abbott’s planning a commercial launch for the device in Europe by the end of 2012, but said it will make select sizes in limited numbers available this year.

Clearances roundup

Abbott touts the device as the "world’s first drug-eluting bio-resorbable vascular scaffold for the treatment of coronary artery disease," but several other companies are also developing bio-resorbable stents. San Diego-based Reva Medical Inc. raised $84.8 million in an initial public offering on the Australian Securities Exchange in December. Arterial Remodeling Technologies, a French company that uses technology developed in part at the Cleveland Clinic, raised $8.5 million in venture capital funding in September to further develop its bio-degradable stents. MultiCell Technologies Inc. (OTC:MCET) is working on a stent that combines two drugs aimed at reducing restenosis — salicylate, aspirin’s active ingredient, and sirolimus. That polymer stent is designed to dissolve completely over the course of a year.

Abbott is planning a 500-patient, 40-site European clinical trial to compare Absorb to Abbott’s Xience Prime drug-eluting stent.

Here’s a roundup of other companies announcing clearances and approvals from the Food & Drug Administration and foreign regulatory agencies:

  • ProGEL Platinum surgical sealant wins CE Mark
    Neomend Inc., a maker of sealant and adhesion-prevention products for the surgical marketplace, announced it has received CE (Conformité Européenne) Mark approval for the company’s ProGEL® PLATINUM Surgical Sealant. “This important milestone will enable us to help surgeons more effectively treat lung air leaks during lung resection surgery in countries outside the U.S., where there are many such procedures due to the prevalence of lung cancer,” said CEO David Renzi in prepared remarks.
    Read more
  • NxStage lands FDA clearance for therapeutic plasma exchange cartridge
    NxStage Medical Inc. (NSDQ:NXTM), a leading manufacturer of innovative dialysis products, announced that it recently received clearance from the Food & Drug Administration to market its Therapeutic Plasma Exchange (TPE) cartridge for use with the NxStage® System One™ in a clinical environment.
    Read more
  • Varian Medical Systems receives 510(k) clearance for its proton therapy system
    Varian Medical Systems (NYSE:VAR) received FDA 510(k) clearance for the Varian Proton Therapy System which generates protons for precision radiotherapy of lesions, tumors, and conditions anywhere where radiation treatment is indicated. It is the first working system capable of delivering precise intensity modulated proton therapy (IMPT) using pencil beam scanning technology.
    Read more
  • diaDexus announces FDA clearance for automated PLAC Test
    diaDexus Inc. (OTC:DDXS), a diagnostics company focused on the development and commercialization of in vitro diagnostic products addressing unmet needs in cardiovascular disease, announced that the FDA has cleared for marketing the automated version of its proprietary PLAC® Test. This PLAC Test product format, based on turbidimetric immunoassay (TIA) technology, is designed to run on most clinical chemistry analyzers, significantly expanding the number of clinical labs and physician offices that are able to offer the PLAC Test.
    Read more
  • Critical Diagnostics receives CE Mark for Presage ST2 assay
    Critical Diagnostics announced that it received CE Mark for its high sensitivity Presage ST2 Assay and is commencing commercialization in Europe. The product is indicated for use as an aid in risk stratification of patients with heart failure or acute coronary syndrome. This regulatory milestone marks the first time that an assay has become commercially available for the clinical measurement of the biomarker soluble ST2.
    Read more
  • Corgenix announces 28 percent increase in reimbursement rate for AspirinWorks test
    The AspirinWorks® Test from Corgenix Medical Corp. (OTC:CONX), reimbursed under CPT code 84431, has received a 28 percent increase in reimbursement according to the 2011 Clinical Laboratory Fee Schedule. The fee schedule is published annually by the Centers for Medicare & Medicaid Services (CMS).
    Read more
  • Viveve obtains CE Mark for gynecologic treatment of vaginal laxity
    Viveve Inc., a development stage women’s health company, announced that it received CE Mark approval for the use of its Viveve System for the non-surgical treatment of laxity of the vaginal introitus, after childbirth, to improve female sexual function.
    Read more
  • Crospon receives FDA approval for EndoFLIP
    Crospon, an Irish medical device developer based in Galway, has announced that the company received clearance from the FDA to market a new imaging catheter for the measurement of sleeves created during bariatric surgery.
    Read more
  • FDA clears ImageSenseTM Technology for use with Colposcopy
    STI Medical Systems, announced that FDA gave clearance to the Company’s precedent-setting ImageSense™ technology for use in colposcopy. This new proprietary technology represents an entirely new way of presenting digital imagery in the doctor’s office, and is first-in-class for colposcopy. This represents an advance in colposcope system technology as colposcopes used in evaluating cervical neoplasia have remained largely unchanged for over 50 years.
    Read more
  • Gore receives FDA approval for GORE C3 delivery system for GORE Excluder AAA endoprosthesis
    W. L. Gore & Associates announced that it has received approval from the FDA to market the GORE® C3 Delivery System to deploy the GORE® EXCLUDER® AAA Endoprosthesis as a minimally invasive treatment for patients suffering from an abdominal aortic aneurysm (AAA). The GORE C3 Delivery System enables physicians and interventionalists to reposition the GORE EXCLUDER Device prior to final release from the delivery catheter.
    Read more
  • Celera files PMA application for KIF6 genotyping assay
    Celera Corp. (NSDQ:CRA) announced that it has submitted a Pre-market Approval application (PMA) to the FDA for its KIF6 Genotyping Assay, a new molecular in vitro diagnostic test designed to detect a marker for risk of coronary heart disease (CHD) independent of traditional risk factors and aid clinical evaluation when statin treatment is being considered.
    Read more

Filed Under: Business/Financial News, News Well Tagged With: Abbott, Bioabsorbable Stents, Gift Bans

In case you missed it

  • How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
  • Zimmer Biomet appoints new chief accounting officer
  • Cook Medical makes next-gen in vitro fertilization incubator available in U.S., Canada
  • Boston Scientific co-founder Peter Nicholas is dead at 80
  • How Boston Scientific uses clinical feedback to advance innovation
  • How Stryker includes users for product design in the digital age
  • DermaSensor wins MedTech Innovator Mid-Stage Companies Pitch Event
  • FDA approves Medtronic’s Onyx Frontier drug-eluting coronary stent
  • Medtronic completes Intersect ENT acquisition
  • Steris rises on Street-beating Q4, sets fiscal 2023 guidance
  • Medtronic must sell Intersect ENT subsidiary to satisfy FTC concerns
  • Abbott partners with Women as One to help more underrepresented clinicians lead trials
  • Lucira Health asks FDA for EUA on molecular at-home COVID/flu test
  • Device commercialization platform AcuityMD raises $31M Series A to fund R&D engineer hiring
  • Abbott announces availability of Xience Skypoint drug-eluting stent in extended sizes
  • GE Healthcare to invest $50M in Pulsenmore to enter homecare segment
  • BD launches automated infectious disease diagnostic platform in the U.S.

RSS From Medical Design & Outsourcing

  • How Stryker includes users for product design in the digital age
    Medical device developers and manufacturers like Stryker (NYSE:SYK) are changing how they approach design as digital technology becomes more crucial. Four Stryker executives shared how the Kalamazoo, Michigan–based orthopedic device giant is thinking differently about medical product development and how health care providers and patients will ultimately use them. The DeviceTalks Boston panel of Stryker… […]
  • DermaSensor wins MedTech Innovator Mid-Stage Companies Pitch Event
    DermaSensor Inc. — the creator of a handheld, point-and-click device to quickly assess skin lesions for cancer risk — is the winner of the MedTech Innovator Mid-Stage Companies Pitch Event.  The Miami-based mid-stage company beat out 1,000 applicants, more than 20 of which competed on-site May 10–11, 2022 at DeviceTalks Boston. DermaSensor walked away with… […]
  • Steris rises on Street-beating Q4, sets fiscal 2023 guidance
    Steris (NYSE:STE) shares ticked up today on fourth-quarter financial results that came in just ahead of the consensus forecast. The infection prevention technology company — headquartered in Dublin, Ireland, and run operationally out of Mentor, Ohio — posted profits of $52.3 million, or 52¢ per share, on sales of $1.2 billion for the three months… […]
  • Lucira Health asks FDA for EUA on molecular at-home COVID/flu test
    Lucira Health (Nasdaq: LHDX) today said it has asked the FDA for an emergency use authorization (EUA) for its combination COVID-19 and flu test. Emeryville, California–based Lucira said the at-home test would be available with a prescription to test for SARS-CoV-2, Influenza A and Influenza B. The Nucleic Acid Amplification Test (NAAT) platform has a… […]
  • Device commercialization platform AcuityMD raises $31M Series A to fund R&D engineer hiring
    AcuityMD said today it has raised $31 million in Series A funding for its medical device commercialization platform. “With our new funding, we plan to double down on R&D by growing our engineering team from 15 to over 40 over the next year,” AcuityMD co-founder and CEO Michael Monovoukas said in a blog post. “We’ll… […]
  • Rockley Photonics announces $81.5M private placement
    Rockley Photonics (NYSE:RKLY) announced today that it entered into agreements for an $81.5 million private placement. Participating investors agreed to purchase $81.5 million in convertible senior secured notes (due 2026) and warrants to purchase 26.5 million Rockley ordinary shares at an exercise price of $5 per share, subject to certain anti-dilution adjustments. Warrants purchased in… […]
  • Stryker leaders talk medtech trends at DeviceTalks Boston: ‘If you’re slow, you’re going to lose’
    The first day of DeviceTalks Boston closed with a panel of Stryker (NYSE:SYK) executives discussing new tools, technologies and strategies in medtech. Digital VP Tracy Robertson, Digital, Robotics, and Enabling Technologies President Robert Cohen and Surgical Technologies VP of Digital Innovation Siddarth Satish offered their thoughts on industry trends in healthcare and at the Kalamazoo,… […]
  • Medtronic’s VC leader discusses risk, returns, strategy and an ‘ugly truth’
    A panel of medtech investors convened today for DeviceTalks Boston included David Neustaedter, VP of venture capital at Medtronic (NYSE: MDT). He’s spent 14 years in the role, including as director of venture capital at Covidien before Medtronic acquired the company. (Read more in his DeviceTalks speaker bio.) Medtronic has more than $500 million in… […]
  • Here’s where Harvard’s engineering dean sees medtech research going
    Surgical robotics, artificial intelligence, and combatting climate change are but some of the priorities that have Harvard’s engineering school dean excited. Speaking today at DeviceTalks Boston, Frank J. Doyle III described the Harvard John A. Paulson School of Engineering and Applied Sciences as a “well-kept secret” historically. But Harvard engineering is staking out a strong position when it… […]
  • gBETA Medtech accelerator picks its next startups
    The gBETA Medtech virtual accelerator today named the five startups that will participate in the spring program leading up to the June 21 showcase day. The five startups for the spring 2022 cohort are: Mother of Fact: This mobile app for moms with babies offers nutrition tracking, preventative monitoring and daily coaching from licensed dietitians… […]
  • FDA warns of potential toxic risk from Fresenius hemodialysis machines
    The FDA is evaluating the risk of exposure to toxic chemicals from silicone tubing used in Fresenius Medical Care (NYSE: FMS) hemodialysis machines. The investigation concerns three models of Fresenius hemodialysis machines: the 2008T, 2008K2, and 2008K. The chemicals — non-dioxin-like (NDL) polychlorinated biphenyl acids (PCBAs) and NDL polychlorinated biphenyls (PCBs) — are in the… […]

Leave a Reply

You must be logged in to post a comment.

Primary Sidebar

DeviceTalks Weekly

May 13, 2022
Our Pre-Post-DeviceTalks Boston episode, also MedtronicTalks replay with Gastro CMO Austin Chiang
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World

Device Talks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our Device Talks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS